SciTech Development Announces IRB Approval for Human Clinical TrialsLead cancer drug candidate, ST-001 nanoFenretinide, has received Institutional Review Board (“IRB”) approval for its upcoming clinical trials for T-Cell Lymphomas. NEWS PROVIDED BY SciTech Development, LLC September 14, 2023 GROSSE POINTE FARMS, Mich., September 14, 2023 (Newswire.com) – SciTech Development (“SciTech” or the “Company”), a clinical-stage…
SciTech Development Raises $2.73 Million in Oversubscribed Financing Round to Advance Clinical Trials for Cancer Treatment NEWS PROVIDED BY SciTech Development, LLC 07 Jun, 2023, 14:54 ET — Financing Provides for the Advancement of Clinical Trials – GROSSE POINTE FARMS, Mich., June 7, 2023 /PRNewswire/ — SciTech Development today announced it has closed a $2.73M…
SciTech and the Plough Center Announce Manufacturing AgreementThe Contract Manufacturing Agreement Will Provide the Clinical Supply of ST-001, SciTech’s Lead Drug Candidate for Cancer NEWS PROVIDED BY SciTech Development, LLC October 20, 2022 GROSSE POINTE FARMS, Mich., October 20, 2022 (Newswire.com) – SciTech Development is pleased to announce that it has signed a $600K manufacturing…
SciTech Development, LLC Announces FDA Acceptance of Investigational New Drug (IND) Application for ST-001 nanoFenretinide in Patients with T-Cell LymphomaCompany will present at Biotech Showcase™ 2020 on Monday, 01/13/20 at 11:15am PST in San Francisco, CA NEWS PROVIDED BY SciTech Development, LLC 23 Dec, 2019, 09:05 ET GROSSE POINTE FARMS, Mich., Dec. 23, 2019 /PRNewswire/…